ISSN: 1859 - 2872
Immunohistochemical expression of CD10, BCL6, MUM1 in diffuse large B cell lymphoma subtypes at 108 Military Central Hospital
Main Article Content
Keywords
Abstract
Objective: To determine the ratio percentage of germinal central B cell and non- germinal central B cell types of diffuse large B cell lymphoma (DLBCL). To evaluate to the expression of markers CD10, BCL6, MUM1 in diffuse large B cell lymphoma. Subject and method: 44 DLBCL patients were determined by markers CD20 or CD79a and were stained with 03 markers CD10, BCL6, MUM1 at 108 Military Central Hospital. Result: The average age of the disease was 58.9 ± 12.4 years; the most of the patients were over 50 years of age. The rate of germinal central B cell type of DLBCL was 31.8% and non-germinal central B cell type of DLBCL was 68.2%. The rate positive expression of markers CD10, BCL6 and MUM1 were 4.5%; 90.9% and 68.2%, respectively. Conclusion: The manifestation of markers CD10, BCL6, MUM1 is significant in the histopathological subdivision of diffuse large B cell lymphoma to determine the exact histopathology types to help clinicians choose the correct treatment regimen and prognosis for the patient.
Article Details
References
2. Bahadir B, Behzatoglu K, Bektas S, Bozkurt ER, Ozdamar SO (2009) CD10 expression in urothelial carcinoma of the badder. Diagn Pathol 4: 38.
3. Batlle-López A, González DV, Mazorra F, Malatxeberria S, Sáez A, Montalban C et al (2016) Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker. Oncotarget 5(7): 18036-18049.
4. Chen Y, Han T, Iqbal J, Irons R, Chan WC, Zhu X et al (2010) Diffuse large B-cell lymphoma in Chinese patients immuno-phenotypic and cytogenetic analysis of 124 cases. Am J Cli Pathol 133: 305-313.
5. Gualco G, Weiss LM, Harrington WJ Jr, Bacchi CE (2009) Nodal diffuse large B-cell lymphomas in children and adolescents: immunohistochemical expression patterns and c-MYC translocation in relation to clinical outcome. Am J Surg Pathol 33: 1815-1822.
6. Guo Y, Takeuchi I, Karnan S, Miyata T, Oshima K, Seto M (2014) Array-comparative genomic hybridization profiling of immunohistochemical subgroups of diffuse large B-cell lymphoma shows genomic alterations. Cancer Sci 105: 481-489.
7. Habara T, Sato Y, Takata K, Iwaki N, Okumura H, Sanobe H et al (2012) Germinal center B-cell-like versus non-germinal center B-cell-like as important prognostic factor for localized nodal DLBCL. J Clin Exp Hematopathol 52: 91-99.
8. Hemandez-llizalituri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR et al (2011) Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-celllike phenotype. Cancer 117: 5058-5066.
9. Huang Y, Ye S, Cao Y, Li Z, Huang J, Huang H, Cai M, Luo R, Lin T (2012) Outcome of R-CHOP or CHOP regimen for germinal center and nongerminal center subtypes of diffuse large B-cell lymphoma of Chinese patients. Sci World J: 8971-8978.
10. Huh J (2012) Epidemiologic overview of malignant lymphoma. Korean J Hematol 47: 92-104.
11. Menon MP, Pittaluga S, Jaffe ES (2012) The histological and biological spectrum of diffuse large B-cell lymphoma in the WHO classification. Cancer J 18: 411-420.
12. Nyman H, Jerkeman M, Karjalainen-Lindsberg M, Banham AH, Leppa S (2009) Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. Mod Pathol 22: 1094-1101.
13. Shaffer AL, Emre NCT, Romesser PB, Staudt LM (2009) IRF4: Immunity. Malignancy! Therapy?. Cli Cancer Res 15: 2954-2961.
14. Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Li Y et al (2012) Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: A report from the International DLBCL rituximab-CHOP consortium program study. Leukemia 26: 2103-2113.
Article Sidebar
